Channel BannerChannel Banner
8a-MTuhfw988a-MTuhfw98

New flu mRNA vac, dangers

237,576
Socialcounts.OrgEnter Fullscreen (f)
15,887
likes
2,560
comments
daily view 0
monthly view 0

Share

Live Analytics

Comments 0

New flu mRNA vac, dangers Analytics Table

Income Estimates for New flu mRNA vac, dangers

Based on this YouTube video's total view count of 237K views and industry-standard rates, the estimated total earning is $166 - $475 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

About New flu mRNA vac, dangers

Explore New flu mRNA vac, dangers with 237,576 views, 15,887 likes, and 2,560 comments. Experience the impact of this video content that has captured audience attention.

Way more side effect from mRNA flu vaccine than traditional vaccine. F.D.A. Approves Moderna’s mRNA Flu Vaccine mFLUSIVA is the first FDA-approved mRNA influenza vaccine. Food and Drug Administration Wednesday 5th August approved the first mRNA flu vaccine Will make it easier to rapidly target a new prevalent or virulent strain of the virus. mFLUSIVA Manufactured by Moderna https://feeds.issuerdirect.com/news-release.html?newsid=4801915282452025&symbol=MRNA&utm_source=chatgpt.com "The FDA approval of mFLUSIVA, our fourth approved product in the United States and the first mRNA-based flu vaccine, demonstrates the continued strength and versatility of our mRNA platform," This approval also reflects the ongoing potential of our mRNA platform to help address important public health challenges through continued scientific innovation. mFLUSIVA Authorized for people ages 50 to 64. Primary FDA references https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-18-2026-meeting-announcement?utm_source=chatgpt.com https://www.fda.gov/media/193210/download?utm_source=chatgpt.com The F.D.A. issued an accelerated approval for adults 65 and older, (allows widespread use and can be converted to a full approval) Moderna expects vaccine ready for 2026-27 respiratory virus season. Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults https://www.nejm.org/doi/full/10.1056/NEJMoa2516491 Encodes hemagglutinin glycoproteins from World Health Organization–recommended influenza strains. H is the surface protein used to attach to human cells The name "hemagglutinin" comes from the proteins ability to cause erythrocytes to clump together The study A total of 40,703 participants. received trivalent mRNA-1010 (20,350 participants) or the standard-dose comparator (20,353 participants) Median follow-up was 181 days RT-PCR–confirmed, influenza-like illness, from at least 14 days after vaccination mRNA-1010 group Positive in 411 of 20,179 recipients (2.0%) Control group Positive in 557 of 20,124 recipients (2.8%) Giving a relative vaccine efficacy of 26.6% 0.8% absolute risk reduction thereby meeting the criteria for noninferiority, superiority, and higher-level superiority. Solicited adverse reactions were more frequent with mRNA-1010 than with the standard-dose comparator injection-site pain in 65.8% vs. 29.8% fatigue in 45.1% vs. 20.3% headache in 37.8% vs. 18.0% myalgia in 35.4% vs. 11.6% Serious adverse events were reported in 2.2% of the recipients of mRNA-1010 Grade 3 solicited adverse reactions were reported by 6.4% of recipients of mRNA-1010 and 1.0% of recipients of the standard-dose comparator Adverse events of special interest in recipients of mRNA-1010 included thrombocytopenia 84 days after vaccination and cardiomyopathy 95 days after vaccination Despite efforts by HHS (Health and Human Services) https://www.hhs.gov/press-room/hhs-winds-down-mrna-development-under-barda.html August, 2025 Secretary Robert F. Kennedy announced a coordinated wind-down of its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority (BARDA) “We reviewed the science, listened to the experts, and acted,” “BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. https://zenodo.org/records/15787612 We’re shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate.” “Let me be absolutely clear: HHS supports safe, effective vaccines for every American who wants them. That’s why we’re moving beyond the limitations of mRNA and investing in better solutions,” News refs https://www.nytimes.com/2026/08/05/health/mrna-flu-vaccine-moderna.html?unlocked_article_code=1.3VA.BfR8.KWHKEmThIMBp&smid=nytcore-ios-share https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-first-mrna-flu-shot-moderna-2026-08-06/?utm_source=chatgpt.com

About YouTube Real-Time View Count

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.

Embed Widget

Parameters:

  • fullscreen=true - Fullscreen counter
  • graph=true - Live graph chart
  • counter=0/1/2 - Select counter (0=likes, 1=views, 2=comments)
URL

Click to copy the embed URL to your clipboard